Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool February 19, 2010 Brian Orelli	Breathe Deep. It Might Not Be That Bad. The FDA strikes down asthma drugs, but will doctors buy in?
The Motley Fool June 25, 2010 Brian Orelli	Merck Breathes Life Into an Acquired Pipeline The acquisition is paying off with newly approved drugs.
American Family Physician September 15, 2004 Matthew Mintz	Asthma Update Part II. Medical Management An evidence-based approach was used to examine several key issues on appropriate medical therapy for patients with asthma. The updated guidelines clarify these issues and should alter the way physicians prescribe asthma medications.
American Journal of Nursing May 2010 Corbridge & Corbridge	Asthma in Adolescents and Adults This article outlines current guideline recommendations for asthma and reviews what clinicians need to teach patients about its pathophysiology, pharmacotherapy, self monitoring, and environmental control.
American Family Physician January 1, 2007 Scow et al.	Leukotriene Inhibitors in the Treatment of Allergy and Asthma Approximately one third of all prescriptions for maintenance therapy in patients with persistent asthma are for leukotriene inhibitors; however, evidence of their effectiveness compared with other treatments is mixed.
Nurse Practitioner April 2010 Benninger & McCallister	Asthma in pregnancy: Reading between the lines Asthma is one of the most common, chronic medical conditions that can complicate pregnancy, affecting between 4% and 8% of this population.
American Family Physician May 15, 2005 Courtney et al.	Childhood Asthma: Treatment Update The prevalence of childhood asthma has risen significantly over the past four decades. This article summarizes the treatment of asthma in children, with an emphasis on new modalities and the results of recent studies.
The Motley Fool February 10, 2011 Brian Orelli	Breathe Easier, Join the Competition Novartis' strategy is a good one.
BusinessWeek November 21, 2005 Catherine Arnst	How To Manage Your Asthma Asthma sufferers can achieve near-perfect freedom from shortness of breath.
The Motley Fool December 8, 2008 Brian Orelli	A Checkup for Makers of Asthma Drugs Because of recent events, GlaxoSmithKline, AstraZeneca, Novartis, and Schering-Plough all face extra scrutiny from the FDA.
The Motley Fool June 11, 2009 Brian Orelli	Kids, Take Your Antipsychotics! Drugs to combat mental illness might gain FDA approval for children.
Chemistry World September 25, 2013 Phillip Broadwith	New respiratory drugs neck and neck A flurry of regulatory approvals has seen three new drugs approved for asthma and chronic obstructive pulmonary disease in the European and Japanese markets.
American Family Physician September 1, 2004 Matthew Mintz	Asthma Update: Part I. Diagnosis, Monitoring, and Prevention of Disease Progression The National Asthma Education and Prevention Program Expert Panel has updated its clinical guidelines on asthma medications, prevention of disease progression, and patient self-management.
The Motley Fool June 11, 2010 Brian Orelli	25 to 0! Now That's a Ringing Endorsement Novartis flies through its advisory panel meeting nearly unscathed.
Chemistry World March 15, 2011 Sarah Houlton	Benlysta breaks 50 year Lupus drug drought The first new treatment for lupus erythematosus in half a century has been approved by the US Food and Drug Administration
The Motley Fool April 25, 2011 Luke Timmerman	Vertex, Merck Step Up to the Public Stage With Hepatitis C Drugs This Week Most analysts see Vertex's drug as best-in-class. But what does the FDA have to say about it?
The Motley Fool January 15, 2010 Brian Orelli	Oops, Sorry About That, Pfizer The FDA says there's no problem with Spiriva after all.
American Family Physician April 1, 2001 James P. Kemp & Judith A. Kemp	Management of Asthma in Children The prevalence of asthma in children has increased 160 percent since 1980, and the disease currently affects nearly 5 million children in the United States...
The Motley Fool July 18, 2005 Karl Thiel	Stocks That Make You Breathe Easier Allergies and asthma are big markets that several firms aim to tackle. Investors, take note.
The Motley Fool December 4, 2007 Brian Orelli	An Early Gift to Drugmakers Drugmakers could be allowed to market for drugs' off-label indications.
Nurse Practitioner December 2010 Kathy J. Morris	Management of Exercise-Induced Bronchospasm in Adolescents with Asthma Collaboration between the nurse practitioner and adolescent is essential to develop an asthma management plan that will provide for optimal physical activity and prevent asthma exacerbations while exercising.
The Motley Fool September 28, 2010 Brian Orelli	Don't Get Stuck! Invest in Needle-Free Drugs Here's how to make some money off society's general disdain for needles through next-generation drugs.
The Motley Fool March 31, 2011 Brian Orelli	Hepatitis C Drugs Heat Up The current hepatitis C drugs stink. Who's ahead in the race to find new ones?
Nursing June 2011 Daniel A. Hussar	New Drugs 2011: Part 2 In this article, you'll learn about seven recently approved drugs, including: fingolimod hydrochloride, an oral drug indicated to treat patients with relapsing forms of multiple sclerosis.
The Motley Fool September 7, 2010 Luke Timmerman	Vertex Nails Third Big Trial With Hepatitis C Drug And in the toughest patients to treat, too.
Pharmaceutical Executive April 1, 2011	Off-Label But On Point? Use of off-label drugs is a balancing act for physicians, and poses even more problems for pharma. The FDA is moving slowly to help.
Chemistry World October 8, 2010 Sarah Houlton	U-turn on Alzheimer's drugs in the UK The UK National Institute for Health and Clinical Excellence proposes that those with mild disease will be able to receive them from early next year, on the basis of growing clinical evidence of their effectiveness.
The Motley Fool December 31, 2010 Brian Orelli	2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions.
The Motley Fool February 23, 2010 Brian Orelli	The One That Didn't Get Away After some encouragement, the FDA approves Gilead's Cayston.
The Motley Fool September 9, 2010 Brian Orelli	Will These Drugs Get Past the FDA This Month? See what the FDA has on its decision calendar for the rest of September.
The Motley Fool June 3, 2011 Brian Orelli	FDA Bullies Obesity Drugmakers It's been clear for some time that the Food and Drug Administration isn't particularly fond of obesity drugs. Now it's just being a bully.
The Motley Fool January 7, 2010 Brian Orelli	Warning: Potential Anemic Growth Ahead Anemia-drug makers get more scrutiny from the FDA.
The Motley Fool November 25, 2011 Brian Orelli	7 Black Friday Biotech Bargains Get in at the right time to maximize your returns.
The Motley Fool January 8, 2008 Brian Orelli	A Painful Reminder From the FDA The agency issues a reminder that osteoporosis drugs can cause severe pain.
The Motley Fool April 28, 2011 Brian Orelli	Victory for Victrelis Merck's hepatitis C drug moves one step closer to FDA approval.
Nursing June 2010 Daniel A. Hussar	New drugs 2010, part 2 In this article, you'll learn about 14 recently marketed new drugs.
The Motley Fool July 8, 2008 Brian Lawler	Blockbuster Drugs Bound for Extinction? One of the biggest classes of prescription drugs, those for diabetes treatments, faces tougher FDA standards.
The Motley Fool May 7, 2007 Mike Havrilla	Critical Therapeutics' Juncture With approval likely, the real challenge will be selling an asthma drug once it's on the market. While shares may get a brief bounce, this may not be a case of "if you approve it, they will prescribe."
The Motley Fool May 21, 2010 Brian Orelli	And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too.
The Motley Fool February 20, 2009 Brian Orelli	The Skinny on Diabetes Drugs The goal of diabetes drugs is to get the patient's blood glucose levels under control, but one class of drugs, called GLP1 agonists, have a nice side effect: weight loss. Which pharma companies can benefit?
Nursing March 2012 Daniel A. Hussar	New Drugs 2012: part I In this article, you'll learn about 11 recently approved drugs.
The Motley Fool December 22, 2006 Stephen Albainy-Jenei	Is Off-Label Off-Base? Off-label prescriptions for uses lacking scientific support account for billions in drug revenue for Eli Lilly. If the FDA takes an aggressive stance on off-label-use marketing, it could significantly shrink drug sales for companies whose revenues are derived largely from such off-label use.
The Motley Fool April 26, 2011 Brian Orelli	There Is Only Downside in Consensus Hepatitis C advisory panels will almost certainly recommend approval. Almost.
The Motley Fool January 21, 2010 Brian Orelli	Here's That Critical Merck Info You Missed Announcing clinical trial failures in a FAQ? Really?
AskMen.com June 22, 2003 Mike Davison	Asthma: Are You At Risk? The recurrent and debilitating effects of asthma sometimes appear suddenly, so it is best to arm yourself with knowledge about this serious and chronic condition.
The Motley Fool March 8, 2010 Brian Orelli	Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting.
American Family Physician March 1, 2003 James C. Higgins	The 'Crashing Asthmatic' Asthma is one of the most common chronic disorders managed by family physicians. A "crashing asthmatic" is a patient with asthma who is clinically deteriorating into respiratory failure or arrest despite initial treatment. Managing such a patient can be a major challenge.
BusinessWeek August 26, 2010 Tom Randall	Cocktails Are Next For Cancer-Drug Makers Taking a cue from the cocktails of drugs that have made AIDS survivable, drugmakers are pursuing combination therapies against cancer.
The Motley Fool July 25, 2011 Brian Orelli	Bristol-Myers' Acquisition Could Pay for Itself It will gain access to potential milestones.
Nursing February 2010 Daniel A. Hussar	New Drugs 2010, PART 1 In this article, you'll learn about 16 new drugs.